1. Scrip
  2. >>Business

Venture Funding Deals, July – August 2016

 
• By Deanna Kamienski, Beth Allan, Maureen Riordan, Steven Muntner, and Amanda Micklus

Ambrx, Arcus, Cleave Biosciences, InflaRx, MonoSol Rx, Nevakar and Tioma Therapeutics were among firms raising more than $30m in venture funding in July and August. Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive review of emerging biopharmaceutical companies that have received venture funding during the past two months.

Coins

Ambrx Inc. (protein therapeutics known as bio-conjugates) raised $45m in a late-stage financing round led by Apricot Capital and Northeast Securities Prosperity Healthcare Fund. (Also see "VC Roundup: Cleave Raises $37m To Maintain Phase I Momentum, Plus $233.5m In Recent Financings" - Scrip, 10 August, 2016.) Sinopharm Capital, Humanwell Healthcare Fund, and existing investors Fosun Pharma, HOPU Investments, and Everbright Limited Healthcare Fund also participated. The company will use the funds to further develop its Phase I asset ARX788 along with its pipeline of ADC candidates and lead immuno-oncology program CD3-folate. After withdrawing from its planned IPO in June 2014, the company was acquired by a consortium consisting of entities affiliated with Shanghai Fosun Pharmaceutical Group Co. Ltd., HOPU Investments, China Everbright Ltd.'s CEL Healthcare Fund, and WuXi PharmaTech Inc. (Aug.) [See Deal]

Arcus Biosciences Inc. (immuno-oncology) raised $70m through its oversubscribed Series B round. The company's initial targeted amount was $50m....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

China Signals Restarting IPOs For Unprofitable Biotechs

 
• By Dexter Jie Yan

The China Securities Regulatory Commission has proposed a new “growth tier” for the STAR Market of the Shanghai Stock Exchange, to reinstate the market’s listing standards for unprofitable firms.

BIO Notebook: Woodcock Calls For Doing The Right Thing, Dealmaking Remains Constrained

 
• By Mandy Jackson, Joseph Haas, and Sarah Karlin-Smith

Highlights from Day Four of the BIO International Convention include Woodcock offering practical advice on rare disease trials, the sorry state of dealmaking mid-year, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.

Syncona Looks To Go Private As Market Decline Deepens

 
• By Andrew McConaghie

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.